ENEman Ayman Nada

Eman Ayman Nada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eman Ayman Nada has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Analgesic efficacy of uni-level erector spinae plane block in breast cancer surgery patients: a systematic review and Meta-analysis

    by Basma M. El-Khalifa, Hamza Khelifa, Mahmoud Mohamed Gad, Jamal Ahmad, Hazem M. Mazy, Asmaa Soliman, Eman Ayman Nada, Bahaa Elfakharany, Tarek H. Elmeneizee, Israa Ahmed Qutob

  • Open Access

    Erector spinae plane block (ESPB) versus paravertebral plane block (PVB) in managing post-operative pain in breast cancer patients: a systematic review and meta-analysis

    by Basma M. El-Khalifa, Hamza Khelifa, Mahmoud Mohamed Gad, Bahaa Elfakharany, Mohamed Sherif Ali Ahmed, Asmaa Soliman, Eman Ayman Nada, Jamal Ahmed, Hazem M. Mazy, Israa Ahmed Qutob

  • Comparative diagnostic performance of [18F] flurpiridaz PET and SPECT myocardial perfusion imaging (MPI): a systematic review and meta-analysis

    by Muataz Kashbour, Sarah Amro, Eman Ayman Nada, Moaz Yasser Darwish, Ahmed Mohamed Hamdy, Sabina Dizdarevic

    This study aimed to synthesise diagnostic evidence comparing a novel myocardial perfusion radiotracer [¹⁸F]flurpiridaz PET with SPECT myocardial perfusion imaging (MPI) in detecting coronary artery disease (CAD). A systematic search to Feb 2026 was conducted in Web of Science, Scopus, PubMed, and the Cochrane Library. Studies comparing [¹⁸F]flurpiridaz PET with SPECT/MPI were screened. Primary outcomes were sensitivity and specificity using invasive coronary angiography as the reference standard. Secondary outcomes included image quality and radiation dose. Out of 558 studies, 28 publications were fully screened, and three trials comparing [¹⁸F]flurpiridaz PET with [⁹⁹ᵐTc]Tc-sestamibi/tetrofosmin SPECT were identified (1476 patients). For ≥ 50% stenosis, pooled sensitivity/specificity were 76% (95% CI 71-81%)/71% (63-78%) for flurpiridaz PET and 61% (53-69%)/76% (60-86%) for SPECT; for ≥ 70% stenosis, values were 87% (77-94%)/63% (52-73%) versus 73% (62-81%)/72% (50-87%), respectively. In patients with BMI ≥30kg/m², sensitivity/specificity were 74% (68-78%)/73% (64-80%) for flurpiridaz PET and 61% (49-72%)/75% (56-88%) for SPECT. In women, sensitivity/specificity were 73% (57-84%)/76% (70-81%) for flurpiridaz PET versus 50% (29-70%)/78% (60-90%) for SPECT. Rest and stress image quality favoured flurpiridaz PET (RR1.29[1.19-1.41] and 1.14[1.11-1.17], both p<0.00001) with superior image quality and lower radiation dose. This first meta-analysis suggests higher sensitivity of [¹⁸F]flurpiridaz PET vs SPECT MPI with significantly lower radiation dose and improved image quality. [¹⁸F]flurpiridaz is especially useful for assessing women and patients with high BMI, given its superior sensitivity and comparable subgroup specificity. However, findings should be interpreted cautiously due to the limited number of studies.


  • Erector spinae plane block (ESPB) versus modified pectoral plane block (PECS II) in managing post modified radical mastectomy pain: A systematic review and meta-analysis

    by Basma M. El-Khalifa, Ahmed S.A. Osman, Eman Ayman Nada, Jamal Ahmad, Asmaa Soliman, Fatma Abouzkaly, Hazem M. Mazy, Bahaa Elfakharany, Ahmed Mohamed Hamdy, Nada S. Jibril, et al.

  • Open Access

    The Safety and Efficacy of the Chikungunya Virus Vaccine: A Systematic Review and Meta Analysis.

    by Eman Ayman Nada, Aya M. Fayod, Abdelrahman Shata, Nereen A. Almosilhy, Amany Mahmoud Genidy, Yasein Fadel Awadalla, Sama M. Mahmoud, Asmaa Zakria Alnajjar, Muataz Kashbour

    Background: Chikungunya virus (CHIKV) infection has an impact on global health, which emphasize the need for effective and safe vaccines. Several clinical trials have evaluated different vaccine platforms, including live-attenuated and virus-like particle (VLP) vaccines. The aim of this study is assessed the immunogenicity and safety of CHIKV vaccines across available clinical trials. Methods: A systematic review and meta-analysis of 11 clinical trials including 12,871 participants was conducted. Four vaccines were evaluated: live-attenuated candidates (VLA1553, TSI-GSD-218) and VLP vaccines (PXVX0317, VRC-CHKVLP059-00-VP). Trials included participants from endemic and non-endemic regions and were predominantly randomized, double-blind, and placebo-controlled. Seroresponse outcomes were examined at 15 days, 1 month, and 6 months. Risk of bias was assessed, and sensitivity analyses were performed to assess heterogeneity. Results: Vaccine recipients showed consistently higher seroresponse rates at all follow-up points. Live attenuated vaccines demonstrated statistically significant and robust immunogenicity at 15 days, 1 month, and 6 months. VLP vaccines generated favorable but non-significant pooled effects, with heterogeneity influenced by individual trials. Safety analyses revealed higher adverse event rates in vaccine groups compared with placebo, primarily driven by live-attenuated vaccines; however, events were mostly mild to moderate. VLP vaccines showed a safety profile similar to placebo. Conclusion: CHIKV vaccine candidates, particularly live-attenuated platforms, demonstrate strong immunogenicity with acceptable safety profiles. VLP vaccines appear safe with moderate immunogenicity. Further long term follow-up and additional large-scale trials are needed to support global vaccine implementation.

  • Open Access

    Efficacy and safety of ropeginterferon alfa-2b in the treatment of polycythemia vera: a systematic review with single arm meta-analysis

    by Eman Ayman Nada, Mohamed Abdelhalim Elfagieh, Fares Abdelsalam, Asmaa Ahmed Elrashedy, Fatima A. Idres, Abdelrahman Shata, Ali M. Othman, Hasan Mohammad Masoum Hamoud, Radwa Mohamed Awadalla, Israa Ahmed Qutob, et al.

    Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by increased red blood cell production, with high risk of venous and arterial thrombosis. Mutations in the JAK2 gene, particularly JAK2 V617F, play a central role in its pathogenesis. Ropeginterferon alfa-2b is a novel long-acting interferon showing promise in managing PV through hematologic and molecular control. This study aimed to evaluate the efficacy and safety of Ropeginterferon alfa-2b in patients with PV based on a systematic review and meta-analysis of available clinical trials. A systematic search was conducted across PubMed, Cochrane Library, Web of Science, Google Scholar, and Scopus on May 8, 2025. Randomized controlled trials (RCTs) assessing Ropeginterferon alfa-2b in PV were included. The PRISMA guidelines were followed, and the protocol was registered in PROSPERO (CRD420251051466). Quality assessment was performed using RoB 2.0 and ROBINS-I tools. A random-effects model was applied using R software. Eight studies involving 761 patients were included and only six studies included in single arm meta-analysis with 328 patients. The pooled proportion of complete hematological response at 12 months was 0.63 (95% CI [0.51–0.73]), with high heterogeneity. Reductions in JAK2 V617F allele burden were significant (MD: 26.57, 95% CI [13.49–39.65]). Molecular response was achieved in 25% (95% CI [0.04–0.70]) of patients. The most common adverse events were elevated liver enzymes (AST: 0.28; ALT: 0.32), influenza-like illness (0.11), and anemia (0.09), with unresolved heterogeneity in all outcomes. Ropeginterferon alfa-2b shows promising efficacy in achieving hematological and molecular responses in patients with PV. However, notable heterogeneity and safety concerns, particularly liver-related adverse effects, warrant further investigation in large-scale trials. Graphical Abstract


  • Open Access

    Knowledge, Attitudes, and Practices of Blood Donation Among Medical Students: A Systematic Review Across Nine Countries

    by Mawadda Chukr, Ahmed O. Mohamady, Fatima Abdallh, Doha Ahmed Farrag, Eman Ayman Nada, Israa Ahmed Qutob, Mahmoud M. Elsayed

    Blood donation is the best source of blood in emergencies and improves others' lives. Globally, 118.54 million blood donations occur annually, with 31.5 donations per 1,000 people in high-income countries compared to 16.4 in upper-middle-income and 5 in low-income countries. The WHO (world Health Organization) insists that countries focus on young people to achieve 100% non-remunerated voluntary blood donation (VBD). Therefore, university students are good candidates for blood donation. This review provides a better understanding of the current status of blood donation among medical students. This review systematically searched international databases (PubMed, Scopus, EMBASE, Web of Science, and Google Scholar) with relevant English studies published in English from 2000 to April 2024. study characteristics (study ID, location, study design, sampling techniques, and university), main outcome measures, and findings were extracted.We included 39 cross-sectional Knowledge, Attitude, and Practice (KAP) studies across nine countries involving 13,895 medical students. Most studies were conducted in India. all studies used different self-administrated tools to collect data. Most of the studies had fair to good quality. Positive attitudes varied widely (42%-92.6%), with the highest rates among Indian students and the lowest among Pakistani students. Donation rates ranged from 1–74%, with Nigerian students demonstrating the highest rates. This review, which analyzed 39 cross-sectional KAP studies from nine countries involving 13,895 medical students, found that most students exhibited moderate levels of knowledge, attitudes, and practices regarding blood donation. To bridge this gap, policymakers must prioritize VBD awareness campaigns, and institutions should facilitate donation opportunities and incentivize participation among medical students.


  • Open Access

    Safety and efficacy of glycopyrronium tosylate in patients with primary axillary hyperhidrosis: a systematic review and meta-analysis

    by Eman Ayman Nada, Abdallah A. Helal, Mallak Eyad Abu Kaddorah, Mohamed Marey Hesn, Suha Younis Hasan, Jeremiah Oluwatomi Itodo Daniel, Mohamed Sayed Zaazouee, Mohamed Abd-ElGawad


  • Open Access

    Efficacy and Safety of Farletuzumab in Ovarian Cancer: A Systematic Review and Single-Arm Meta-Analysis

    by Aya M Fayoud, Moaz Yasser Darwish, Eman Ayman Nada, Abdallah A Helal, Nada Shaaban Mohamed, Asmaa Ahmed Elrashedy, Mohamed Abd-ElGawad

    Folate receptor alpha (FRα) has emerged as a promising target in the treatment of ovarian cancer, with farletuzumab, a humanized monoclonal antibody targeting FRα, showing potential in clinical settings. This systematic review and single-arm meta-analysis aimed to evaluate the efficacy and safety of farletuzumab in patients with solid tumors, particularly ovarian cancer. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a thorough search across PubMed, the Web of Science, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) for clinical trials assessing farletuzumab in solid tumors. Data were extracted on study characteristics, patient demographics, treatment regimens, and efficacy outcomes including progression-free survival (PFS), overall survival (OS), response rates, and adverse events (AEs). The pooled analyses were performed using the Open Meta-Analyst software.